Q-omics provides the consensus-scored NANOGNB profile across patient tissues and cancer cell-line models. NANOGNB expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NANOGNB is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, NANOGNB RNA expression shows 7,746 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, and TGCT as cancer lineages where NANOGNB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANOGNB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANOGNB survival associations across molecular data types. NANOGNB RNA expression shows survival associations in the most cancer types (12), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANOGNB RNA expression–survival associations across cancer types. High NANOGNB expression shows unfavorable associations in KICH, ACC, MESO, LUAD and LAML, but favorable associations in SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for NANOGNB RNA expression.
This table summarizes NANOGNB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NANOGNB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANOGNB shows lower tumor expression in KICH and KIRC and higher tumor expression in LUSC and HNSC. The KICH box plot shows higher NANOGNB RNA expression in normal versus tumor tissue (log2 FC = −0.030, t-test p = .004).
This table shows molecular features associated with NANOGNB in patient tissues and cancer cell lines. In patient samples, NANOGNB shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NANOGNB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
